In Phase A, participants will obtain distinctive doses and schedules of oral ABBV-744 tablet to recognize Harmless dosing regimen. Extra members will be enrolled on the determined monotherapy dosign program. In Phase B, contributors will receive oral ruxolitinib and ABBV-744 is going to be specified as "increase-on" therapy. In Segment https://brennush554tfp7.scrappingwiki.com/user